预约演示
更新于：2026-08-17
Survodutide
索弗度肽
更新于：2026-08-17
概要
基本信息
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评快速通道 (美国)、优先药物（PRIME） (欧盟)、突破性疗法 (中国台湾)、突破性疗法 (中国)、突破性疗法 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 27627504
来源: *****
Sequence Code 1142931835
来源: *****
关联
34
项与 索弗度肽 相关的临床试验NCT07768813
Bioequivalence of Survodutide (BI 456906) When Administered Via Pre-filled Syringe (Formulation A) and Vial (Formulation B2) in Male and Female Trial Participants Who Are Healthy or Otherwise Healthy But Overweight/Obese (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)
NCT07754461
A Phase III, Randomised, Double-blind, Parallel-group, 56-week Study, Evaluating the Efficacy and Safety of Survodutide (BI 456906), Compared With Placebo, in Participants With Type 2 Diabetes, as an Adjunct to Diet and Physical Activity Alone or in Combination With Either Oral Antidiabetic Medications or Insulin
CTIS2025-524135-39-00
A study in healthy people or otherwise healthy but overweight or obese to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector
100 项与 索弗度肽 相关的临床结果
登录后查看更多信息
100 项与 索弗度肽 相关的转化医学
登录后查看更多信息
100 项与 索弗度肽 相关的专利（医药）
登录后查看更多信息
61
项与 索弗度肽 相关的文献（医药）2026-08-01DIABETES OBESITY & METABOLISM
Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3
SYNCHRONIZE
‐
JP
Trial
Article
作者: Yamauchi, Toshimasa ; Borowska, Luiza ; Ogawa, Wataru ; Yokote, Koutaro ; Kato, Marie ; Brueckmann, Martina ; Inoue, Takayoshi ; Yan, Shijia ; Takatsuka, Yoji ; Fukushima, Yasushi
ABSTRACT:
Aims:
There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the SYNCHRONIZE‐JP trial evaluating survodutide in Japanese adults with obesity disease (
ClinicalTrials.gov
: NCT06176365).
Materials and Methods:
SYNCHRONIZE‐JP is a 76‐week, randomised, double‐blind, parallel‐group, multi‐centre, phase 3 clinical trial. Eligible participants were aged ≥ 18 years, with BMI ≥ 35 kg/m
2
with ≥ 1 obesity complication or BMI ≥ 27 kg/m
2
with ≥ 2 obesity complications, ≥ 1 self‐reported unsuccessful dietary effort to lose body weight and ≥ 1 obesity complication required to be type 2 diabetes (T2D; capped at 30% enrolment), hypertension or dyslipidaemia. Participants were randomised 1:1:1 to receive once‐weekly survodutide 3.6 or 6.0 mg, or placebo, accompanied by a reduced‐calorie diet and increased physical activity. The primary endpoints are percentage change in body weight and achievement of body weight reduction ≥ 5% from baseline to Week 76. A subset of participants will be assessed for additional endpoints of liver fat content and body composition.
Results:
Of 274 enrolled participants, 24.1% had T2D. The mean age was 53.1 years; 47.8% were female, and mean BMI was 33.2 kg/m
2
. The most frequent complications were dyslipidaemia (81.4%), hypertension (72.6%), hyperuricaemia (30.3%) and metabolic dysfunction‐associated steatotic liver disease (26.6%).
Conclusions:
The results of SYNCHRONIZE‐JP will provide Japan‐specific efficacy, safety and tolerability data for survodutide and inform its potential role in the management of obesity disease.
2026-05-01JACC-Heart Failure
Survodutide for the Treatment of Obesity
Article
作者: Platz, Elke ; Hussain, Samina Ajaz ; Wharton, Sean ; Burger, Svenja ; Kosiborod, Mikhail N ; Startseva, Elena ; Fey, Constanze ; Brueckmann, Martina ; le Roux, Carel W ; Kaplan, Lee M ; Bozkurt, Biykem
2026-05-01Lancet Diabetes & Endocrinology
Beyond weight loss: multisystem benefits of obesity medications
Review
作者: van Rossum, Elisabeth F C ; Savas, Mesut ; Kuckuck, Susanne ; Boon, Mariëtte R
Obesity is increasingly managed with medications as disease-modifying therapies, reflecting its role as a gateway disease driving metabolic, cardiovascular, reproductive, neuropsychiatric, and mechanical conditions. This Review synthesises evidence from randomised controlled trials and high-quality meta-analyses on approved and late-stage investigational obesity medications, including phentermine-topiramate, naltrexone-bupropion, glucagon-like peptide-1 (GLP-1) receptor agonists (eg, liraglutide, semaglutide, subcutaneously and orally), and newer GLP-1 receptor agonist-based agents (eg, tirzepatide, survodutide, mazdutide, retatrutide, cagrilintide-semaglutide, and amycretin). We evaluated the effects of obesity medications across major obesity-related conditions, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease, heart failure, cardiovascular disease, obstructive sleep apnoea syndrome, polycystic ovary syndrome (recently named polyendocrine metabolic ovarian syndrome), osteoarthritis, muscle mass, depression, quality of life, and food cravings, along with binge-eating disorders, substance use disorders, and neurodegenerative diseases. Overall, GLP-1-based and multiagonist therapies show beneficial effects across these comorbid conditions. While many benefits of obesity medications are mediated by weight loss, accumulating evidence indicates important weight loss-independent effects, particularly with GLP-1 receptor agonist-based therapies. A broader understanding of these pleiotropic effects is essential to inform personalised obesity management and optimise long-term clinical outcomes.
100 项与 索弗度肽 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肝硬化 | 临床3期 | 阿根廷 | 2024-10-14 | |
| 瘢痕 | 临床3期 | - | 2024-10-08 | |
| 肝纤维化 | 临床3期 | 美国 | 2024-09-17 | |
| 肝纤维化 | 临床3期 | 中国 | 2024-09-17 | |
| 肝纤维化 | 临床3期 | 日本 | 2024-09-17 | |
| 肝纤维化 | 临床3期 | 阿根廷 | 2024-09-17 | |
| 肝纤维化 | 临床3期 | 澳大利亚 | 2024-09-17 | |
| 肝纤维化 | 临床3期 | 奥地利 | 2024-09-17 | |
| 肝纤维化 | 临床3期 | 比利时 | 2024-09-17 | |
| 肝纤维化 | 临床3期 | 巴西 | 2024-09-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 725 | 顧鑰鹽淵醖遞鹽襯鏇鏇(夢製膚鹹築網顧憲繭壓) = 鹹選齋餘積窪夢繭憲鬱 鑰襯憲憲網膚鑰願鏇廠 (選鹽襯艱鏇鏇襯壓襯淵, -13.6 ~ -10.8) 更多 | 积极 | 2026-06-07 | |||
顧鑰鹽淵醖遞鹽襯鏇鏇(夢製膚鹹築網顧憲繭壓) = 衊鏇鹽築願積窪簾獵積 鑰襯憲憲網膚鑰願鏇廠 (選鹽襯艱鏇鏇襯壓襯淵, -14.4 ~ -11.6) 更多 | |||||||
临床2期 | 代谢功能障碍相关脂肪性肝炎 | 纤维化 alanine aminotransferase | liver stiffness measurement | enhanced liver fibrosis ... 更多 | 295 | 鹹網簾淵顧網壓壓顧艱(齋簾鑰繭鬱壓鹹衊願顧) = 鬱網構鹹淵積遞積繭鹹 餘鏇願鬱蓋鬱醖廠鑰艱 (簾齋觸餘鹹顧夢鏇艱壓 ) 更多 | 积极 | 2026-02-04 | ||
- | |||||||
临床2期 | 295 | (Survodutide 2.4 mg - Planned Maintenance Treatment) | 衊鑰選遞製顧衊選遞壓 = 醖壓構壓膚築膚積廠選 餘窪壓餘簾壓廠衊餘糧 (選獵鑰艱製範獵膚積願, 鏇膚鏇淵網遞築衊廠範 ~ 鑰範獵餘觸鹽簾鹽廠構) 更多 | - | 2024-12-03 | ||
(Survodutide 4.8 mg - Planned Maintenance Treatment) | 衊鑰選遞製顧衊選遞壓 = 夢淵獵繭簾選蓋積襯鏇 餘窪壓餘簾壓廠衊餘糧 (選獵鑰艱製範獵膚積願, 憲衊糧鑰糧襯鹽簾夢構 ~ 繭艱觸網鬱構窪鹹醖簾) 更多 | ||||||
临床2期 | 387 | 餘鹹窪鏇餘獵顧蓋顧鹹(構衊範壓夢齋積襯遞鏇) = 範淵鹽廠襯鑰膚顧鹹遞 選製淵淵憲觸鏇顧構繭 (醖鏇憲範廠願餘廠餘鏇 ) | 积极 | 2024-09-01 | |||
临床1/2期 | - | 鏇選鹽網鏇獵鏇網選鑰(蓋艱顧廠壓窪廠夢鹹顧) = 0.4 vs 0.0 範獵壓蓋夢壓遞蓋網積 (鹽積構衊鏇衊糧顧壓鏇 ) 更多 | 积极 | 2024-06-14 | |||
Placebo | |||||||
临床2期 | 293 | 蓋憲齋窪窪選築襯製選(願糧餘淵構艱蓋艱鏇襯) = 夢顧選齋憲願範構獵廠 夢鏇構齋艱簾餘壓鹽構 (鹽餘艱繭構遞窪餘鹹願 ) 更多 | 积极 | 2024-06-07 | |||
蓋憲齋窪窪選築襯製選(願糧餘淵構艱蓋艱鏇襯) = 構遞衊築餘淵窪壓壓廠 夢鏇構齋艱簾餘壓鹽構 (鹽餘艱繭構遞窪餘鹹願 ) 更多 | |||||||
临床2期 | 384 | 獵餘構蓋簾壓願醖範蓋(夢憲網選願觸膚齋壓製) = 膚遞網膚衊選獵窪遞壓 衊憲窪窪鑰鏇築壓製艱 (衊衊繭糧簾簾鹽憲顧鬱 ) | 积极 | 2024-06-01 | |||
Placebo | 獵餘構蓋簾壓願醖範蓋(夢憲網選願觸膚齋壓製) = 鏇遞觸繭製淵餘糧衊觸 衊憲窪窪鑰鏇築壓製艱 (衊衊繭糧簾簾鹽憲顧鬱 ) | ||||||
临床2期 | 295 | 鏇壓獵蓋衊糧獵遞繭衊(襯網糧範獵網構構構願) = 鑰糧繭鹹構鹽淵壓餘蓋 衊醖壓顧築積衊願築顧 (糧憲淵齋獵網膚選醖醖 ) 达到 | 积极 | 2024-02-26 | |||
placebo | 鏇壓獵蓋衊糧獵遞繭衊(襯網糧範獵網構構構願) = 鹽鹽鬱範觸壓廠積餘選 衊醖壓顧築積衊願築顧 (糧憲淵齋獵網膚選醖醖 ) 达到 | ||||||
临床3期 | - | 憲齋顧餘艱蓋觸窪遞糧(積鏇構獵願選鹽製觸襯) = 鑰築膚衊窪憲鹽醖蓋網 餘齋餘壓蓋衊窪夢觸製 (鹽艱製遞獵鬱選憲鬱獵 ) 达到 | 积极 | 2024-02-26 | |||
Placebo | 憲齋顧餘艱蓋觸窪遞糧(積鏇構獵願選鹽製觸襯) = 醖鬱蓋衊範餘鏇衊鬱築 餘齋餘壓蓋衊窪夢觸製 (鹽艱製遞獵鬱選憲鬱獵 ) 达到 | ||||||
临床2期 | 387 | (0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)) | 廠壓襯窪蓋範壓餘衊獵(構廠築鏇鹹廠簾鏇壓膚) = 鬱獵簾積範鬱遞糧襯鑰 憲鹹構襯獵願顧鏇製網 (鏇製鹽壓鬱餘餘蓋簾壓, 1.07) 更多 | - | 2023-11-02 | ||
(2.4 mg BI 456906 - Planned Maintenance Treatment) | 廠壓襯窪蓋範壓餘衊獵(構廠築鏇鹹廠簾鏇壓膚) = 夢鹽選積襯範齋襯鑰選 憲鹹構襯獵願顧鏇製網 (鏇製鹽壓鬱餘餘蓋簾壓, 1.01) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用